Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Program, including the introduction of Stelara ...

Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...

Topline data readouts from multiple Phase 2 studies expected throughout 2025VTX2735 in patients with recurrent pericarditis in H2VTX3232 in ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and ...

Daniela Soto, 25, lives in Los Angeles and was diagnosed with ulcerative colitis (UC) when she was just 21. If you don’t know ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, said Tuesday it has launched its biosimilar product ...

Biocon Biologics has introduced a biosimilar drug, YESINTEK, in the U.S. for treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. The launch represents a commitment to ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ...